Literature DB >> 25120023

High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.

Xiangjun Lyu1, Hongzhao Li, Xin Ma, Xintao Li, Yu Gao, Dong Ni, Donglai Shen, Liangyou Gu, Baojun Wang, Yu Zhang, Xu Zhang.   

Abstract

S100A6 (calcyclin), functions in cell cycle progression and differentiation, has been reported to promote the tumorigenesis and malignancy of many types of cancers. Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC, lacking both promising prognostic markers and effective therapeutic targets. In our previous study, we have found the elevated S100A6 in the ccRCC tumor tissues, and the differentially expressed genes determined by microarray analysis were found to be strongly related to tumor metastasis after S100A6 knockdown and overexpression in the ccRCC cell line 786-O. The mRNA expression of S100A6 detected by RT-PCR in 6 cell lines and 174 tumor tissues, including 58 metastatic ccRCC and 116 clinicopathological features paired non-metastatic ccRCC (1:2), indicated S100A6 was elevated in the metastatic cells and tumor tissues. The protein expression was consistent with mRNA expression. The biological function of S100A6 in promoting metastasis was determined through overexpression and knockdown of S100A6 in the ccRCC cell lines 786-O, caki-1, and ACHN. In the scratch wound migration assay as well as migration and invasion assays, S100A6 knockdown significantly suppressed the migratory and invasive abilities of tumor cells, whereas overexpression enhanced the malignancy. Further research with the follow-up data of 129 ccRCC patients were analyzed by the Cox regression and survival analysis. The expression of S100A6 was up-regulated in metastatic ccRCC cells. In the metastatic tumor tissues, the expression of S100A6 was also higher than in the non-metastatic tissues. High S100A6 expression might be crucial to promote metastasis in ccRCC by enhancing the ability of tumor cells migration and invasion. In addition, the quantitative mRNA expression of S100A6 in the tumor tissues was an independent risk factor and might be used as a prognostic marker for the metastatic risk of the localized T1-T2 stage ccRCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25120023     DOI: 10.1007/s12013-014-0196-x

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.194


  9 in total

1.  Serum levels of S100A6 are unaltered in patients with resectable cholangiocarcinoma.

Authors:  Sven H Loosen; Fabian Benz; Jennifer Niedeggen; Maximilian Schmeding; Florian Schüller; Alexander Koch; Mihael Vucur; Frank Tacke; Christian Trautwein; Christoph Roderburg; Ulf P Neumann; Tom Luedde
Journal:  Clin Transl Med       Date:  2016-09-27

2.  Increased expression of S100A6 promotes cell proliferation in gastric cancer cells.

Authors:  Xiao-Hong Wang; Hong Du; Lin Li; Duan-Fang Shao; Xi-Yao Zhong; Ying Hu; Yi-Qiang Liu; Xiao-Fang Xing; Xiao-Jing Cheng; Ting Guo; Shen Li; Zi-Yu Li; Zhao-De Bu; Xian-Zi Wen; Lian-Hai Zhang; Jia-Fu Ji
Journal:  Oncol Lett       Date:  2016-11-22       Impact factor: 2.967

3.  Distinct prognostic values of S100 mRNA expression in breast cancer.

Authors:  Shizhen Zhang; Zhen Wang; Weiwei Liu; Rui Lei; Jinlan Shan; Ling Li; Xiaochen Wang
Journal:  Sci Rep       Date:  2017-01-04       Impact factor: 4.379

4.  "Stealth dissemination" of macrophage-tumor cell fusions cultured from blood of patients with pancreatic ductal adenocarcinoma.

Authors:  Gary A Clawson; Gail L Matters; Ping Xin; Christopher McGovern; Eric Wafula; Claude dePamphilis; Morgan Meckley; Joyce Wong; Luke Stewart; Christopher D'Jamoos; Naomi Altman; Yuka Imamura Kawasawa; Zhen Du; Loren Honaas; Thomas Abraham
Journal:  PLoS One       Date:  2017-09-28       Impact factor: 3.240

5.  CancerSEA: a cancer single-cell state atlas.

Authors:  Huating Yuan; Min Yan; Guanxiong Zhang; Wei Liu; Chunyu Deng; Gaoming Liao; Liwen Xu; Tao Luo; Haoteng Yan; Zhilin Long; Aiai Shi; Tingting Zhao; Yun Xiao; Xia Li
Journal:  Nucleic Acids Res       Date:  2019-01-08       Impact factor: 16.971

6.  Integrative Radiogenomics Approach for Risk Assessment of Post-Operative Metastasis in Pathological T1 Renal Cell Carcinoma: A Pilot Retrospective Cohort Study.

Authors:  Hye Won Lee; Hwan-Ho Cho; Je-Gun Joung; Hwang Gyun Jeon; Byong Chang Jeong; Seong Soo Jeon; Hyun Moo Lee; Do-Hyun Nam; Woong-Yang Park; Chan Kyo Kim; Seong Il Seo; Hyunjin Park
Journal:  Cancers (Basel)       Date:  2020-04-02       Impact factor: 6.639

Review 7.  Curcuminoids as Modulators of EMT in Invasive Cancers: A Review of Molecular Targets With the Contribution of Malignant Mesothelioma Studies.

Authors:  Daniel L Pouliquen; Alice Boissard; Cécile Henry; Olivier Coqueret; Catherine Guette
Journal:  Front Pharmacol       Date:  2022-07-08       Impact factor: 5.988

8.  A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma.

Authors:  Adele M Alchahin; Shenglin Mei; Philip J Saylor; David B Sykes; Peter V Kharchenko; Ninib Baryawno; Ioanna Tsea; Taghreed Hirz; Youmna Kfoury; Douglas Dahl; Chin-Lee Wu; Alexander O Subtelny; Shulin Wu; David T Scadden; John H Shin
Journal:  Nat Commun       Date:  2022-09-30       Impact factor: 17.694

9.  Biomarkers of tumor invasiveness in proteomics (Review).

Authors:  Daniel L Pouliquen; Alice Boissard; Olivier Coqueret; Catherine Guette
Journal:  Int J Oncol       Date:  2020-05-28       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.